🔗 Share this article

As the US continues making sweeping changes to its vaccine recommendations, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by casting doubt on Covid shots in the pandemic and has zeroed in on possible deaths after COVID-19 immunization in her short time at the Food and Drug Administration.

Planned Shifts to Pediatric Vaccine Schedule

Public health authorities were set to unveil major revisions to the childhood immunization program recently, bringing the US with the Danish immunization schedule, it is understood – a substantial departure that would place the US out of alignment with a large portion of the international standard with little proof for improved outcomes. The planned update has been pushed back until the next year.

Instead of the top vaccines chief, Høeg is set to present at the event. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to head the office this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has often pushed for ending certain childhood vaccine recommendations in the US so as to align more similar to Denmark's approach, a country with universal health coverage and a population roughly the population of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccines – typically the domain of Dr. Prasad, head of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Qualifications

The appointee has little discernible experience in pharmaceutical research, oversight or leadership, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and CBER since March.

“She doesn’t seem to have any of the qualifications” for running the drug-regulation department, said Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in leading a major agency. She has no expertise in pharmaceutical oversight.”

Former heads of the center would “grasp laws and regulations and the research of drug development”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who ran the center have had.”

The drug center has an enormous range of responsibilities at the agency, the former commissioner stated.

“Many people just focuses on the new drug program, but the generic program approves thousands of generic medications. There’s a biosimilars program, over-the-counter program and other areas, and all of those need to be managed,” she said. “The responsibility you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a significant leadership component to the position, which manages in excess of 5,000 employees. “It’s a massive leadership role, if you execute it properly,” she concluded.

Agency Reaction and Contentious Programs

When asked about inquiries about Dr. Høeg's fitness for the role and whether this appointment signifies greater collaboration among FDA leaders on vaccines, a spokesperson stated that the “inquiries stem from inaccurate assumptions”.

“Her resume matches the duties of her role,” the spokesperson said, citing the period Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg takes over the agency head's new fast-track approval initiative, a controversial expedited therapy clearance system that allegedly troubled her predecessors. “How are these therapies being chosen for this expedited pathway? Who is making the decisions?” Howard said. “There is a lot of confidentiality happening at the FDA right now.”

Overall, he stated, “the FDA looks to be trending towards more relaxed oversight of pharmaceuticals, with the exception of shots.”

Established History on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if concerning, past, some experts have noted. She authored a research paper using unconfirmed public submissions to determine the rate of heart inflammation following COVID-19 vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are riskier than they are.

Part of her “desired changes” for the new administration included altering rules for novel immunizations and discontinuing “optional” immunizations, she remarked after the election on a podcast. At the FDA, Dr. Høeg has allegedly proposed preventing teenage boys from obtaining Covid vaccines.

“She is an thorough dogmatist who begins with her preconceived notions and tailors the evidence to accommodate the evidence in a extremely deceptive, fraudulent fashion,” Howard stated.

Taking Control and a “Revenge Tour”

Høeg became part of other dissenters, {like|